Homocysteine-lowering effect of 500 μg folic acid every other day versus 250 μg/day

Annals of Nutrition and Metabolism

Volumn 44, Issue 5-6, 2000, Pages 194-197

  Brouwer, I A ^a,b   Van Rooij, I A L M ^b   Van Dusseldorp, M ^a   Thomas, C M G ^b   Blom, H J ^b   Hautvast, J G A J ^a   Eskes, T K A B ^b   Steegers Theunissen, R P M ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Folate; Folic acid; Homocysteine; Women

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG EFFECT; ENZYME SUBSTRATE; FOLIC ACID BLOOD LEVEL; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; NEURAL TUBE DEFECT; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INTERVENTION STUDIES; NEURAL TUBE DEFECTS; TIME FACTORS;

EID: 0034526110     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046683     Document Type: Article

References (15)

1. Ward M, McNulty H, McPartlin J, et al: Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q J Med 1997;90:519-524.
2. Homocysteine Lowering Trialists' Collaboration: Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998;316:894-898.
3. Brouwer IA, van Dusseldorp M, Thomas CMG, et al: Low-dose folic acid supplementation decreases plasma homocysteine: A randomized trial. Am J Clin Nutr 1999;69:99-104.
4. Steegers-Theunissen RPM, Boers GH, Trijbels FJ, et al: Maternal hyperhomocysteinemia: A risk factor for neural-tube defects? Metabolism 1994;43:1475-1480.
5. Mills JL, McPartlin JM, Kirke PN, et al: Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345: 149-151.
6. Boushey CJ, Beresford SA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
7. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for cardiovascular disease. JAMA 1997;277:1775-1781.
8. Jacob RA, Wu MM, Henning SM, et al: Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 1994;124: 1072-1080.
9. Kelly P, McPartlin JM, Goggins M, et al: Unmetabolized folic acid in serum: Acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997;65:1790-1795.
10. Wagner C: Biochemical role of folate in cellular metabolism; in Bailey L (ed): Folate in Health and Disease. New York, Dekker, 1995, pp 23-42.
11. Shane B: Folate chemistry and metabolism, in Bailey LB (ed): Folate in Health and Disease. New York, Dekker, 1995, pp 1-22.
12. Fiskerstrand T, Refsum H, Kvalheim G, et al: Homocysteine and other thiols in plasma and urine: Automated determination and sample stability. Clin Chem 1993;39:263-271.
13. te Poele-Pothoff MT, van den Berg M, Franken DG, et al: Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995;32:218-220.
14. Malinow MR, Duell PB, Hess DL, et al: Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015.
15. Schorah CJ, Devitt H, Lucock M, et al: The responsiveness of plasma homocysteine to small increases in dietary folic acid: A primary care study. Eur J Clin Nutr 1998;52:407-411.